Lead Product(s) : 2-Fucosyllactose-Synthetic
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Phoenix Biotech Acquisition Corp.
Deal Size : $136.0 million
Deal Type : Termination
Details : OM002 is a synthetic biology-produced human milk oligosaccharide (HMO) 2’-fucosyllactose, or 2’FL. The single most abundant HMO is 2’FL, which constitutes nearly 30% of the total HMO proportion in human milk.
Brand Name : OM002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : 2-Fucosyllactose-Synthetic
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Phoenix Biotech Acquisition Corp.
Deal Size : $136.0 million
Deal Type : Termination
Lead Product(s) : 2-Fucosyllactose-Synthetic
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Phoenix Biotech Acquisition Corp.
Deal Size : $136.0 million
Deal Type : Merger
Details : Anticipated cash resources will fund a Phase 2b clinical trial of Intrinsic’s lead, HMO-based drug candidate, OM002 (2’-fucosyllactose, or 2’FL), in over 400 patients with the constipation dominant form of irritable bowel syndrome (IBS-C).
Brand Name : OM002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 31, 2022
Lead Product(s) : 2-Fucosyllactose-Synthetic
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Phoenix Biotech Acquisition Corp.
Deal Size : $136.0 million
Deal Type : Merger
LOOKING FOR A SUPPLIER?